Latest Capital Raises News

American Rare Earths has raised A$15 million through a well-supported placement to accelerate its Halleck Creek rare earths project in Wyoming, signalling a strategic pivot with new leadership focused on U.S. operations.

Titomic has launched a major US manufacturing hub in Alabama, secured key defense contracts, and expanded leadership to accelerate its global additive manufacturing ambitions.

Sun Silver Limited has raised $30 million through a major institutional placement to accelerate drilling and development at its flagship Maverick Springs Silver-Gold Project in Nevada.

Orange Minerals NL has raised $810,000 to fund exploration and due diligence on its new Tepa Gold Project acquisition in Ghana, while advancing promising Australian projects with notable assay results.

West Coast Silver has raised over $6 million through a share placement to accelerate exploration at its high-grade Elizabeth Hill silver project, signalling strong investor confidence and ambitious growth plans.

Catalyst Metals reported steady gold production in the June 2025 quarter, progressing development at its Trident project while completing key corporate transactions that strengthen its growth outlook.

InVert Graphite Limited has successfully raised $3.5 million and resumed ASX trading following key acquisitions and promising initial trench results at its Morogoro Graphite Project.

Novonix Limited reports significant progress in its synthetic graphite anode materials production, benefiting from new US tariffs on Chinese imports and strategic leadership appointments. The company also secures up to US$100 million in convertible debenture funding to support expansion plans.

Catalyst Metals has locked in a three-year A$100 million revolving credit facility with major banks, bolstering its financial flexibility without immediate debt drawdown. This move strengthens its balance sheet as it advances development at the Plutonic Gold Belt.

NOVONIX has entered a multi-tranche funding agreement with Yorkville Advisors to raise up to US$100 million through convertible debentures, supporting its Riverside facility build-out and commercial production ramp-up.

Island Pharmaceuticals reported promising Phase 2a/b trial results for its dengue drug ISLA-101 and secured a strategic acquisition of the broad-spectrum antiviral Galidesivir, bolstering its pipeline and balance sheet.

Prospech Limited has reported a 90% increase in its Korsnäs rare earth element resource in Finland, alongside progressing key metallurgical test work and exploring promising copper-gold targets in Slovakia.